## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($85.18)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Zimmer Biomet to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: Sahm | 20251223T080843 | Neutral | Relevance: 100%
- Zimmer Biomet Holdings, Inc. announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 8:15 a.m. PT. A live webcast of the presentation will be available on Zimmer Biomet's Investor Relations website. The company, a global medical technology leader, develops innovative products and integrated digital and robotic technologies to enhance patient mobility and health.

**2. Wedge Capital Management L L P NC Sells 17,263 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251222T130823 | Neutral | Relevance: 100%
- Wedge Capital Management L.L.P. NC has reduced its stake in Zimmer Biomet Holdings, Inc. by 21.3%, selling 17,263 shares and retaining 63,914 shares valued at approximately $6.296 million. The medical equipment provider recently reported Q3 EPS of $1.90, beating analyst estimates, and announced a quarterly dividend of $0.24. Analysts currently have a consensus "Hold" rating on ZBH stock with a target price of $107.50.

**3. Douglas Lane & Associates LLC Purchases 29,011 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251221T100848 | Neutral | Relevance: 100%
- Douglas Lane & Associates LLC increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.2% in the third quarter, purchasing an additional 29,011 shares. This brings their total holdings to 431,360 shares, valued at approximately $42.49 million. The company currently has a "Hold" rating from analysts with a consensus target price of $107.50, and recently reported Q3 EPS of $1.90, beating estimates.

**4. Benson Investment Management Company Inc. Acquires New Position in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251221T080857 | Somewhat-Bullish | Relevance: 100%
- Benson Investment Management Company Inc. has acquired a new position of 50,430 shares in Zimmer Biomet Holdings, Inc. worth approximately $4.97 million during the third quarter. Institutional investors now own about 88.89% of the medical equipment provider's stock. Zimmer Biomet recently reported strong quarterly earnings and revenue, while setting optimistic FY2025 guidance.

**5. Zimmer Biomet to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: PR Newswire | 20251222T123208 | Neutral | Relevance: 100%
- Zimmer Biomet Holdings, Inc. announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 8:15 a.m. PT. A live webcast of the presentation will be available on Zimmer Biomet's Investor Relations website, with an archived replay accessible afterward. Zimmer Biomet is a global medical technology leader focusing on maximizing mobility and improving health through innovative products and integrated digital and robotic technologies.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Baird | $100 | $117 | -15% |
| 2025-12-11 | Citigroup | $94 | $98 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Baird | down | Neutral |
| 2025-12-11 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-5.0% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 8.8% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Forward P/E 10.5x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $17.7B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 10.5 |
| Current P/E | 10.9 |
| YoY Growth | 4.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.9% to -3.1% (-5.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.1pp (needs >3.0% for momentum thesis). Below SMA200 (0.91x), long-term trend not supportive. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.06% (CS: 17) | Weak |
| RSI_14 | 39.3 | Neutral |
| MACD Histogram | -0.26 | Bearish |
| vs SMA20 | 0.963x | Below |
| vs SMA50 | 0.945x | Below |
| vs SMA200 | 0.912x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $89.44
- **Stop Loss:** $85.18 (4.8% risk)
- **Target:** $93.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 281
- **Position Value:** $25,132.64
- **Portfolio %:** 25.13%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*